Exploring the Predictive Value of Gut Microbiome Signatures for Therapy Intensification in Patients With Inflammatory Bowel Disease: A 10-Year Follow-up Study
Uloženo v:
| Název: | Exploring the Predictive Value of Gut Microbiome Signatures for Therapy Intensification in Patients With Inflammatory Bowel Disease: A 10-Year Follow-up Study |
|---|---|
| Autoři: | Al Radi, Zainab M.A., Prins, Femke M., Collij, Valerie, Vila, Arnau Vich, Festen, Eleonora A.M., Dijkstra, Gerard, Weersma, Rinse K., Klaassen, Marjolein A.Y., Gacesa, Ranko |
| Zdroj: | ISSN:1078-0998 ; ISSN:1536-4844 ; Inflammatory Bowel Diseases, vol. 30 (10), (1642-1653. |
| Informace o vydavateli: | Oxford University Press (OUP) |
| Rok vydání: | 2024 |
| Témata: | Science & Technology, Life Sciences & Biomedicine, Gastroenterology & Hepatology, inflammatory bowel disease, therapy intensification, prognostic tools, gut microbiome, SURGERY, Humans, Gastrointestinal Microbiome, Female, Follow-Up Studies, Male, Adult, Retrospective Studies, Inflammatory Bowel Diseases, Feces, Middle Aged, Metagenomics, Prognosis, Predictive Value of Tests, Biomarkers, Young Adult, 1103 Clinical Sciences, 3202 Clinical sciences |
| Popis: | BACKGROUND: Inflammatory bowel diseases (IBDs) pose a significant challenge due to their diverse, often debilitating, and unpredictable clinical manifestations. The absence of prognostic tools to anticipate the future complications that require therapy intensification presents a substantial burden to patient private life and health. We aimed to explore whether the gut microbiome is a potential biomarker for future therapy intensification in a cohort of 90 IBD patients. METHODS: We conducted whole-genome metagenomics sequencing on fecal samples from these patients, allowing us to profile the taxonomic and functional composition of their gut microbiomes. Additionally, we conducted a retrospective analysis of patients' electronic records over a period of 10 years following the sample collection and classified patients into (1) those requiring and (2) not requiring therapy intensification. Therapy intensification included medication escalation, intestinal resections, or a loss of response to a biological treatment. We applied gut microbiome diversity analysis, dissimilarity assessment, differential abundance analysis, and random forest modeling to establish associations between baseline microbiome profiles and future therapy intensification. RESULTS: We identified 12 microbial species (eg, Roseburia hominis and Dialister invisus) and 16 functional pathways (eg, biosynthesis of L-citrulline and L-threonine) with significant correlations to future therapy intensifications. Random forest models using microbial species and pathways achieved areas under the curve of 0.75 and 0.72 for predicting therapy intensification. CONCLUSIONS: The gut microbiome is a potential biomarker for therapy intensification in IBD patients and personalized management strategies. Further research should validate our findings in other cohorts to enhance the generalizability of these results. ; sponsorship: R.K.W. is supported by a VIDI grant (016.136.308) from the Netherlands Organization for Scientific Research (NWO) and a Diagnostics Grant ... |
| Druh dokumentu: | article in journal/newspaper |
| Popis souboru: | application/pdf |
| Jazyk: | English |
| Relation: | https://lirias.kuleuven.be/handle/20.500.12942/745444; https://doi.org/10.1093/ibd/izae064; https://pubmed.ncbi.nlm.nih.gov/38635882 |
| DOI: | 10.1093/ibd/izae064 |
| Dostupnost: | https://lirias.kuleuven.be/handle/20.500.12942/745444 https://hdl.handle.net/20.500.12942/745444 https://lirias.kuleuven.be/retrieve/144f033a-1bfd-46ce-a72b-54526f59730c https://doi.org/10.1093/ibd/izae064 https://pubmed.ncbi.nlm.nih.gov/38635882 |
| Rights: | info:eu-repo/semantics/openAccess ; public ; https://creativecommons.org/licenses/by-nc/4.0/ |
| Přístupové číslo: | edsbas.B9371517 |
| Databáze: | BASE |
Nájsť tento článok vo Web of Science | Abstrakt: | BACKGROUND: Inflammatory bowel diseases (IBDs) pose a significant challenge due to their diverse, often debilitating, and unpredictable clinical manifestations. The absence of prognostic tools to anticipate the future complications that require therapy intensification presents a substantial burden to patient private life and health. We aimed to explore whether the gut microbiome is a potential biomarker for future therapy intensification in a cohort of 90 IBD patients. METHODS: We conducted whole-genome metagenomics sequencing on fecal samples from these patients, allowing us to profile the taxonomic and functional composition of their gut microbiomes. Additionally, we conducted a retrospective analysis of patients' electronic records over a period of 10 years following the sample collection and classified patients into (1) those requiring and (2) not requiring therapy intensification. Therapy intensification included medication escalation, intestinal resections, or a loss of response to a biological treatment. We applied gut microbiome diversity analysis, dissimilarity assessment, differential abundance analysis, and random forest modeling to establish associations between baseline microbiome profiles and future therapy intensification. RESULTS: We identified 12 microbial species (eg, Roseburia hominis and Dialister invisus) and 16 functional pathways (eg, biosynthesis of L-citrulline and L-threonine) with significant correlations to future therapy intensifications. Random forest models using microbial species and pathways achieved areas under the curve of 0.75 and 0.72 for predicting therapy intensification. CONCLUSIONS: The gut microbiome is a potential biomarker for therapy intensification in IBD patients and personalized management strategies. Further research should validate our findings in other cohorts to enhance the generalizability of these results. ; sponsorship: R.K.W. is supported by a VIDI grant (016.136.308) from the Netherlands Organization for Scientific Research (NWO) and a Diagnostics Grant ... |
|---|---|
| DOI: | 10.1093/ibd/izae064 |